Free Trial

CytomX Therapeutics (CTMX) Earnings Date, Estimates & Call Transcripts

CytomX Therapeutics logo
$0.89 +0.02 (+2.30%)
(As of 11/22/2024 ET)

CytomX Therapeutics Latest Earnings Summary

Upcoming Q4
Earnings Date
Mar. 10Estimated
Actual EPS
(Nov. 7)
$0.07 Beat By $0.23
Consensus EPS
(Nov. 7)
-$0.16

CytomX Therapeutics released Q3 2024 earnings on November 7, 2024, reporting an EPS of $0.07, which topped analysts' consensus estimates of -$0.16 by $0.23. Quarterly revenue was reported to be $33.43 million, above analyst estimates of $18.92 million. With a trailing EPS of $0.17 and a P/E Ratio of 5.24, CytomX Therapeutics' earnings are expected to decrease next year, from ($0.13) to ($0.42) per share.

CTMX Upcoming Earnings

CytomX Therapeutics' next earnings date is estimated for Monday, March 10, 2025, based off prior year's reporting schedules.

Get CytomX Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CytomX Therapeutics and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

CTMX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

CTMX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

CytomX Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20242-$0.20$0.02-$0.09
Q2 20242$0.01$0.16$0.09
Q3 20242$0.01$0.15$0.08
Q4 20242-$0.19-$0.01-$0.10
FY 20248-$0.37$0.32-$0.03
Q1 20251-$0.02-$0.02-$0.02
Q2 20251-$0.03-$0.03-$0.03
Q3 20251-$0.03-$0.03-$0.03
Q4 20251-$0.04-$0.04-$0.04
FY 20254($0.12)($0.12)($0.12)

CytomX Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks
3/10/2025
(Estimated)
------- 
11/7/2024Q3 2024-$0.16$0.07+$0.23$0.07$18.92M$33.43M    
8/8/2024Q2 2024-$0.07-$0.08 -$0.01-$0.08$21.79M$25.12M      
5/8/2024Q1 2024-$0.06$0.17+$0.23$0.17$23.40M$41.46M  
3/11/2024Q4 2023$0.02$0.01 -$0.01$0.01$23.36M$26.61M  
11/7/2023Q3 2023-$0.17$0.04+$0.21$0.04$17.38M$26.38M  
8/8/2023Q2 2023-$0.19-$0.02+$0.17-$0.02$17.38M$24.72M  
5/9/2023Q1 2023-$0.16-$0.05+$0.11-$0.05$22.25M$23.50M  
3/27/2023Q4 2022-$0.21-$0.42 -$0.21-$0.42$17.71M$0.95M  

CytomX Therapeutics Earnings - Frequently Asked Questions

CytomX Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 10th, 2025 based off last year's report dates. Learn more on CTMX's earnings history.

In the previous quarter, CytomX Therapeutics (NASDAQ:CTMX) reported $0.07 earnings per share (EPS) to beat the analysts' consensus estimate of ($0.16) by $0.23. Learn more on analysts' earnings estimate vs. CTMX's actual earnings.

The conference call for CytomX Therapeutics's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for CytomX Therapeutics's latest earnings report can be read online.
Read Transcript

CytomX Therapeutics (NASDAQ:CTMX) has a recorded annual revenue of $101.21 million.

CytomX Therapeutics (NASDAQ:CTMX) has a recorded net income of -$570,000.00. CTMX has generated $0.17 earnings per share over the last four quarters.

CytomX Therapeutics (NASDAQ:CTMX) has a trailing price-to-earnings ratio of 5.24.

CytomX Therapeutics's earnings are expected to decrease from ($0.13) per share to ($0.42) per share in the next year.

`

More Earnings Resources from MarketBeat



This page (NASDAQ:CTMX) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners